Tag: remdesivir

Whistleblower: Remdesivir linked to 601 military deaths

A military whistleblower has released documents, known as “The Remdesivir Papers,” revealing that 601 military service members died after being treated with the controversial antiviral drug remdesivir for suspected COVID-19 cases. The documents claim the drug was administered months before it was approved by the FDA, with serious concerns about data manipulation and lack of informed consent in the trials.

The whistleblower, using the pseudonym Daniel LeMay, shared the documents with investigative journalist J.M. Phelps, exposing that many trial results were kept secret and highlighting remdesivir’s potential role in hundreds of untimely deaths. According to LeMay, the Department of Defense’s Joint Trauma System manipulated trial data to favor remdesivir, and participants were often not informed about the risks involved.

Advocacy groups and former victims of COVID-19 hospital protocols, including those involving remdesivir, have expressed outrage, calling for greater accountability. Gail Seiler, a survivor of remdesivir treatment, stated that the papers “only scratch the surface” of the harm caused by the drug in both military and civilian hospitals.

Keep reading

Massive WHO Study Shows Remdesivir Doesn’t Lower COVID-19 Mortality

Another speedbump has emerged in the drive to produce reliable COVID-19 therapeutics as a highly anticipated WHO drug trial called Solidarity found that Gilead’s COVID-19 treatment, remdesivir, had no substantial effect on a COVID-19 patient’s chances of survival. It also found that three other therapeutics were similarly ineffective.

The FT called the data a “significant blow” to efforts to find a drug that could help save late-stage COVID-19 patients. What’s more, none of the drugs “substantially affected mortality” or reduce the need to ventilate patients.

Other drugs examined in the trial included hydroxychloroquine, lopnavir and interferon regimes. All of them had “little effect” on hospitalized patients.

Keep reading